• 1
    Mansouri A,Ridgway LD,Korapati AL,Zhang Q,Tian L,Wang Y,Siddik ZH,Mills GB,Claret FX. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003; 278: 1924556.
  • 2
    Sato S,Kigawa J,Minagawa Y,Okada M,Shimada M,Takahashi M,Kamazawa S,Terakawa N. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer 1999; 86: 130713.
  • 3
    Fraser M,Leung BM,Yan X,Dan HC,Cheng JQ,Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 2003; 63: 70818.
  • 4
    Sasaki H,Sheng Y,Kotsuji F,Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000; 60: 565966.
  • 5
    Dan HC,Sun M,Kaneko S,Feldman RI,Nicosia SV,Wang HG,Tsang BK,Cheng JQ. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 540512.
  • 6
    Abedini MR,Qiu Q,Yan X,Tsang BK. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 2004; 23: 69977004.
  • 7
    Asselin E,Mills GB,Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001; 61: 18628.
  • 8
    Li J,Feng Q,Kim JM,Schneiderman D,Liston P,Li M,Vanderhyden B,Faught W,Fung MF,Senterman M,Korneluk RG,Tsang BK. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 2001; 142: 37080.
  • 9
    Perego P,Giarola M,Righetti SC,Supino R,Caserini C,Delia D,Pierotti MA,Miyashita T,Reed JC,Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 55662.
  • 10
    Righetti SC,Della Torre G,Pilotti S,Menard S,Ottone F,Colnaghi MI,Pierotti MA,Lavarino C,Cornarotti M,Oriana S,Bohm S,Bresciani GL, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 68993.
  • 11
    Song K,Cowan KH,Sinha BK. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Oncol Res 1999; 11: 1539.
  • 12
    Miyashita T,Krajewski S,Krajewska M,Wang HG,Lin HK,Liebermann DA,Hoffman B,Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799805.
  • 13
    Villunger A,Michalak EM,Coultas L,Mullauer F,Bock G,Ausserlechner MJ,Adams JM,Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 10368.
  • 14
    Wong HK,Fricker M,Wyttenbach A,Villunger A,Michalak EM,Strasser A,Tolkovsky AM. Mutually exclusive subsets of BH3-only proteins are activated by the p53 and c-Jun N-terminal kinase/c-Jun signaling pathways during cortical neuron apoptosis induced by arsenite. Mol Cell Biol 2005; 25: 873247.
  • 15
    Hoffman WH,Biade S,Zilfou JT,Chen J,Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 324757.
  • 16
    Mirza A,McGuirk M,Hockenberry TN,Wu Q,Ashar H,Black S,Wen SF,Wang L,Kirschmeier P,Bishop WR,Nielsen LL,Pickett CB, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 261322.
  • 17
    Erster S,Mihara M,Kim RH,Petrenko O,Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to dna damage that can precede p53 target gene activation. Mol Cell Biol 2004; 24: 672841.
  • 18
    Mihara M,Erster S,Zaika A,Petrenko O,Chittenden T,Pancoska P,Moll UM. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 57790.
  • 19
    Jiang M,Wei Q,Wang J,Du Q,Yu J,Zhang L,Dong Z. Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis. Oncogene 2006; 25: 405666.
  • 20
    Chipuk JE,Bouchier-Hayes L,Kuwana T,Newmeyer DD,Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005; 309: 17325.
  • 21
    Unger T,Sionov RV,Moallem E,Yee CL,Howley PM,Oren M,Haupt Y. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 1999; 18: 320512.
  • 22
    Bulavin DV,Saito S,Hollander MC,Sakaguchi K,Anderson CW,Appella E,Fornace AJ,Jr. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18: 684554.
  • 23
    Shono T,Tofilon PJ,Schaefer TS,Parikh D,Liu TJ,Lang FF. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res 2002; 62: 106976.
  • 24
    Bellacosa A,de Feo D,Godwin AK,Bell DW,Cheng JQ,Altomare DA,Wan M,Dubeau L,Scambia G,Masciullo V,Ferrandina G,Benedetti Panici P, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64: 2805.
  • 25
    Cheng JQ,Godwin AK,Bellacosa A,Taguchi T,Franke TF,Hamilton TC,Tsichlis PN,Testa JR. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 926771.
  • 26
    Sun M,Wang G,Paciga JE,Feldman RI,Yuan ZQ,Ma XL,Shelley SA,Jove R,Tsichlis PN,Nicosia SV,Cheng JQ. AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 4317.
  • 27
    Yuan ZQ,Sun M,Feldman RI,Wang G,Ma X,Jiang C,Coppola D,Nicosia SV,Cheng JQ. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19: 232430.
  • 28
    Yuan ZQ,Feldman RI,Sussman GE,Coppola D,Nicosia SV,Cheng JQ. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 2003; 278: 2343240.
  • 29
    Gottlieb TM,Leal JF,Seger R,Taya Y,Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002; 21: 1299303.
  • 30
    Mayo LD,Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98: 11598603.
  • 31
    Ogawara Y,Kishishita S,Obata T,Isazawa Y,Suzuki T,Tanaka K,Masuyama N,Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277: 2184350.
  • 32
    Zhou BP,Liao Y,Xia W,Zou Y,Spohn B,Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3: 97382.
  • 33
    Yamaguchi A,Tamatani M,Matsuzaki H,Namikawa K,Kiyama H,Vitek MP,Mitsuda N,Tohyama M. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J Biol Chem 2001; 276: 525664.
  • 34
    Fraser M,Chan SL,Chan SS,Fiscus RR,Tsang BK. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene 2006; 25: 220312.
  • 35
    Sasaki H,Kotsuji F,Tsang BK. Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein. Gynecol Oncol 2002; 85: 33950.
  • 36
    Wang Y,Chan S,Tsang BK. Involvement of inhibitory nuclear factor-κB (NFκB)-independent NFκB activation in the gonadotropic regulation of X-linked inhibitor of apoptosis expression during ovarian follicular development in vitro. Endocrinology 2002; 143: 273240.
  • 37
    Tewari M,Quan LT,O'Rourke K,Desnoyers S,Zeng Z,Beidler DR,Poirier GG,Salvesen GS,Dixit VM. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81: 8019.
  • 38
    Honda R,Tanaka H,Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420: 257.
  • 39
    Ashcroft M,Kubbutat MH,Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 1999; 19: 17518.
  • 40
    Ashcroft M,Taya Y,Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000; 20: 322433.
  • 41
    Chehab NH,Malikzay A,Stavridi ES,Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 1999; 96: 1377782.
  • 42
    Fuchs SY,Adler V,Pincus MR,Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 1998; 95: 105416.
  • 43
    Shieh SY,Ikeda M,Taya Y,Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91: 32534.
  • 44
    Chao C,Herr D,Chun J,Xu Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 2006; 25: 261522.
  • 45
    Yaginuma Y,Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992; 52: 41969.
  • 46
    Mujoo K,Zhang L,Klostergaard J,Donato NJ. Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement. Int J Gynecol Cancer 2000; 10: 10514.
  • 47
    Akeshima R,Kigawa J,Takahashi M,Oishi T,Kanamori Y,Itamochi H,Shimada M,Kamazawa S,Sato S,Terakawa N. Telomerase activity and p53-dependent apoptosis in ovarian cancer cells. Br J Cancer 2001; 84: 15515.
  • 48
    Kigawa J,Sato S,Shimada M,Takahashi M,Itamochi H,Kanamori Y,Terakawa N. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001; 14: 16571.
  • 49
    Reles A,Wen WH,Schmider A,Gee C,Runnebaum IB,Kilian U,Jones LA,El-Naggar A,Minguillon C,Schonborn I,Reich O,Kreienberg R, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 298497.
  • 50
    Lavarino C,Pilotti S,Oggionni M,Gatti L,Perego P,Bresciani G,Pierotti MA,Scambia G,Ferrandina G,Fagotti A,Mangioni C,Lucchini V, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000; 18: 393645.
  • 51
    Song K,Li Z,Seth P,Cowan KH,Sinha BK. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Oncol Res 1997; 9: 6039.
  • 52
    Vasey PA,Jones NA,Jenkins S,Dive C,Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996; 50: 153640.
  • 53
    Cregan SP,Arbour NA,Maclaurin JG,Callaghan SM,Fortin A,Cheung EC,Guberman DS,Park DS,Slack RS. p53 activation domain 1 is essential for PUMA upregulation and p53-mediated neuronal cell death. J Neurosci 2004; 24: 1000312.
  • 54
    Brown R,Clugston C,Burns P,Edlin A,Vasey P,Vojtesek B,Kaye SB. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993; 55: 67884.
  • 55
    Chen J,Halappanavar SS,St-Germain JR,Tsang BK,Li Q. Role of Akt/protein kinase B in the activity of transcriptional coactivator p300. Cell Mol Life Sci 2004; 61: 167583.
  • 56
    Iyer NG,Chin SF,Ozdag H,Daigo Y,Hu DE,Cariati M,Brindle K,Aparicio S,Caldas C. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci USA 2004; 101: 738691.
  • 57
    Oda K,Arakawa H,Tanaka T,Matsuda K,Tanikawa C,Mori T,Nishimori H,Tamai K,Tokino T,Nakamura Y,Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102: 84962.
  • 58
    Dumaz N,Meek DW. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 1999; 18: 700210.
  • 59
    Yang X,Fraser M,Moll UM,Basak A,Tsang BK. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006; 66: 312636.
  • 60
    Nemajerova A,Erster S,Moll UM. The post-translational phosphorylation and acetylation modification profile is not the determining factor in targeting endogenous stress-induced p53 to mitochondria. Cell Death Differ 2005; 12: 197200.
  • 61
    Limesand KH,Schwertfeger KL,Anderson SM. MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells. Mol Cell Biol 2006; 26: 884056.
  • 62
    Petty R,Evans A,Duncan I,Kurbacher C,Cree I. Drug resistance in ovarian cancer—the role of p53. Pathol Oncol Res 1998; 4: 97102.
  • 63
    Mi RR,Ni H. MDM2 sensitizes a human ovarian cancer cell line. Gynecol Oncol 2003; 90: 23844.
  • 64
    Pestell KE,Hobbs SM,Titley JC,Kelland LR,Walton MI. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 2000; 57: 50311.
  • 65
    Mano Y,Kikuchi Y,Yamamoto K,Kita T,Hirata J,Tode T,Ishii K,Nagata I. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 1999; 35: 121419.